About Cerecin
Cerecin is a company based in Singapore (Singapore) founded in 2001. Cerecin has raised $265.68 million across 14 funding rounds from investors including Nestlé, KB Securities and Wilmar International. Cerecin operates in a competitive market with competitors including T3D Therapeutics, Alzheon, Longeveron, Alchemab and Totus Medicines, among others.
- Headquarter Singapore, Singapore
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
$4.47 M (USD)-5as on Dec 31, 2021
-
Net Profit
$80.5 K (USD)-72as on Dec 31, 2021
-
EBITDA
Not available
-
Total Equity Funding
$265.68 M (USD)
in 14 rounds
-
Latest Funding Round
$3.74 M (USD), Series C
Jun 10, 2024
-
Investors
Nestlé
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cerecin
Unlock access to complete
Unlock access to complete
Funding Insights of Cerecin
Cerecin has successfully raised a total of $265.68M across 14 strategic funding rounds. The most recent funding activity was a Series C round of $3.74 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cerecin
Cerecin has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Nestlé, KB Securities and Wilmar International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
PE firm investing in South Korea and the US
|
Locked | Locked | Locked | |
|
Investment solutions are provided by M Capital for various sectors.
|
Locked | Locked | Locked |
Investor details for Cerecin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cerecin
Investment portfolio details for Cerecin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cerecin
Detailed financials for Cerecin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cerecin Comparisons
Peer comparison for Cerecin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cerecin
Cerecin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Alzheon, Longeveron, Alchemab and Totus Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Genome-scale drug discovery platform is provided for treating multiple diseases.
|
Detailed competitors of Cerecin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cerecin
Complete news archive for Cerecin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cerecin
Cerecin was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Cerecin is headquartered in Singapore, Singapore.
Cerecin is a funded company, having raised a total of $265.68M across 14 funding rounds to date.
Annual revenue of Cerecin is $4.47M as on Dec 31, 2021.
Cerecin was founded in 2001 in Singapore and operates in the biotechnology sector focused on Alzheimers treatments. Medical foods containing ketone bodies and medium-chain triglycerides are developed to support memory and cognition. An oral formulation of aricaprilin, a medium-chain triglyceride that promotes ketosis and enhances mitochondrial metabolism, is also offered for Alzheimers management. Operations are centered in Singapore.
Cerecin's top competitors include Alzheon, Longeveron and Alchemab.
Cerecin has 13 investors. Key investors include Nestlé, KB Securities, Wilmar International, SK Securities, and Hana Financial Group.